Breaking News: Gilead Sciences Halts Six Idelalisib Combination Trials from Patient Power on Vimeo.
Translating basic science and clinical breakthroughs into language we all can understand
Thursday, March 17, 2016
Wednesday, March 2, 2016
Ibrutinib rejected in England
Before the deafening calls for single payer health care overwhelm any thoughtful discussion about how to pay for crazy expensive medications, I thought this article highlights just how much autonomy is removed in such a system.
England Rejects Ibrutinib in CLL
While our system is definitely a broken mess, at least we can prescribe Ibrutinib without having a major fight with insurance in most cases.
England Rejects Ibrutinib in CLL
While our system is definitely a broken mess, at least we can prescribe Ibrutinib without having a major fight with insurance in most cases.
Subscribe to:
Posts (Atom)